Intensified glucose lowering in type 2 diabetes: time for a reappraisal
- 2.4k Downloads
KeywordsCardiovascular disease Glycaemic control Guidelines Type 2 diabetes Risk factors Risk reduction
Coronary heart disease
Collaborators on Trials of Lowering Glucose
Number needed to treat
Quality-adjusted life years
UK Prospective Diabetes Study
Obesity, urbanisation and an ageing population combine to drive a dramatic increase in the global prevalence of type 2 diabetes , a condition in which the morbidity and mortality from cardiovascular disease substantially outweigh the risk of microvascular complications such as renal disease . Statins and antihypertensive agents lower cardiovascular risk in type 2 diabetes, but the benefits of intensified glucose-lowering remain controversial in this context—management recommendations tend to be based on extrapolation from surrogate endpoints. Recent studies have shown that intensified glycaemic control has limited impact on cardiovascular disease, but there is little indication that entrenched positions in the debate have been affected.
Intensified glucose-lowering is more difficult to achieve, and has a greater negative impact on quality of life, than lowering cholesterol or blood pressure . Nonetheless, and despite questionable benefits to the individual, substantial pressure has been exerted on patients and practitioners to achieve rigorous glycaemic targets. This article examines the evidence for and against intensified glucose-lowering therapy in type 2 diabetes.
From magic bullets to risk reduction
Insulin was justifiably regarded as a near-miracle when first introduced , and antibiotics were equally life-saving . These were true ‘magic bullets’, with a number needed to treat (NNT) of close to one. The scenario changed when drugs were given to people with no symptoms or evidence of vascular disease in order to reduce the possibility of future vascular events. Even drugs that reduce cardiovascular risk by 25%, such as the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors , would (assuming a 20% risk of a CVD event in 10 years), require 20 such people to be treated for 10 years to prevent one event. For any given year of treatment, 199 of 200 people would have an identical outcome with or without the drug. The benefits of such therapy are therefore more apparent at a public health level than at the level of an individual patient, a point that may be disregarded in clinical decision-making and in promotional material. Furthermore, there may be a substantial change in the risk–benefit ratio if the intervention is complex, inconvenient or associated with troublesome side effects.
Hyperglycaemia: risk marker or risk factor for cardiovascular disease?
Symptoms of type 2 diabetes are relatively easy to bring under control, and glucose-lowering treatment beyond this point is designed to reduce the risk of a variety of unwanted outcomes . Let us emphasise that there are no arguments in favour of poor glucose control, since mortality increases substantially in those with HbA1c levels over 8–9%, regardless of therapy , and there can be no doubt that the burden of complications would be greatly reduced if all patients could maintain an HbA1c levels at around 7.5%. The point at issue relates to the benefits, costs and risks of lowering HbA1c levels from about 8%, a relatively achievable target, to about 7% or below in type 2 diabetes.
Cardiovascular disease and glucose control
There is a clear epidemiological relationship between levels of HbA1c and the risk of cardiovascular disease in patients with type 2 diabetes. Epidemiological data from the UK Prospective Diabetes Study (UKPDS) showed a 14% decrease in risk of myocardial infarction and 12% decrease in risk of stroke for each 1% decrease in usual mean level of HbA1c . The meta-analysis of Selvin et al. reported comparable reductions of 13% and 17%, respectively, per 1% change in HbA1c . Questions regarding the reversibility of this risk, first raised by publication of the University Group Diabetes Program Study , have taken some 40 years to resolve. To take one example, the UKPDS  showed a borderline significant 16% reduction in risk of myocardial infarction with intensive therapy, but a non-significant 11% increase in stroke risk, implying that even a study of 3,867 individuals treated for 10 years was insufficiently powered to enable a clear conclusion.
Three further major cardiovascular outcome studies of intensive glycaemic control in patients with type 2 diabetes have appeared over the past 2 years: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study , the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial  and Veterans Affairs Diabetes Trial (VADT) . None found a significant reduction in cardiovascular events in intensively treated patients, and the ACCORD study actually reported a 22% increase in total deaths in this group. The availability of data on 140,278 person-years of treatment does, however, allow more precise estimates of the impact on individual endpoints.
The epidemiological and interventional relationships of cholesterol, blood pressure and HbA1c with cardiovascular disease
Cholesterol (1 mmol/l)
NNT for 5 years
Blood pressure (10/5 mmHg)
NNT for 5 years
Glycaemia (HbA1c 0.9%)
NNT for 5 years
Cholesterol, blood pressure and hyperglycaemia, the three major continuously distributed risk factors for cardiovascular disease, were compared in terms of their epidemiological associations and their reversibility . Table 1 shows the observed relationship between these three variables and the incidence of CHD and stroke in major reviews [25, 26, 27]. Table 1 also provides data on the effect of risk factor lowering, obtained from meta-analyses of interventions for cholesterol , blood pressure  and glycaemia (; ESM Table 1). Since the benefits of intervention are generally dependent on the degree of risk factor reduction, the units used for comparison in each case are the approximate mean changes in the variable achieved in intervention studies. The data in the table suggest that glycaemia is a substantially weaker risk factor for CHD than cholesterol or blood pressure, and very much weaker than blood pressure when it comes to stroke. All three interventions cancelled out most of the excess risk for CHD, but this was not the case with respect to stroke, for which cholesterol and blood pressure lowering appear fully to reverse the excess risk, whereas intensive glycaemic control is without significant benefit. This suggests that the benefits of cardiovascular risk reduction with antihypertensive and lipid-lowering therapies greatly outweigh the benefits of intensive glucose-lowering, especially in older patients with type 2 diabetes whose main risk is that of macrovascular complications .
The benefits of intensified glucose control are typically experienced over the longer term. Older patients, or those with a reduced life expectancy, will therefore experience diminishing benefit. This point is often emphasised in current guidelines, but the practical implications have not been explored in any detail. Recent studies, which have used modelling techniques to estimate the impact of glycaemic control on life expectancy, are enlightening in this respect [33, 34]. The UKPDS outcomes model estimated that intensified glucose control would increase quality-adjusted life years (QALY) by 0.27, or about 99 days . Huang et al.  estimated that intensive control would add 106 days of life expectancy to an otherwise healthy newly diagnosed diabetic patient aged 60–64 years, decreasing with increasing comorbidities, longer duration of disease, or advancing age to only five to eight additional days. Kahn et al. modelled the impact of cardiovascular prevention in a simulated population matching that of the US . This model estimated that patients with diabetes would gain an additional 2.3 QALY with reduction of HbA1c to below 7% for up to 30 years. All three models estimated life expectancy gains by factoring out the impact of the risk marker under investigation. This approach assumes full reversibility of the impact of that variable on events, an assumption which may be less valid for stroke or cardiovascular mortality than for total coronary events when it comes to glucose control (Table 1) [22, 23]. It might even be suggested on this basis that intensified glycaemic control influences the cause of death more than its rate. An alternative actuarial approach, which makes no such assumptions about reversibility, was used (in the pre-HMG-CoA reductase inhibitor era), to calculate the benefits of lipid and blood pressure treatment , but has not been applied to glycaemia. This analysis found that the risk factor that had the greatest impact on life expectancy, and that was most reversible, was smoking cessation. Another study using this approach explored the theoretical impact on absolute risk only of combination therapy .
To summarise, four large clinical trials have shown no increase in life expectancy, or indeed quality of life , in response to intensified diabetes therapy. Epidemiological estimates do imply relatively modest improvements in life expectancy, but highlight the fact that these will be greatest in younger and healthier patients. No demonstrated benefit is present for those with established CHD. To put this in perspective, some 65% of people with diabetes are aged 60 years or above and 38% are over the age of 70 years , and 80% of 65-year-old people suffer three or more chronic conditions, regardless of diabetes status . Current estimates suggest that the benefits of intensified glucose-lowering therapy with respect to life expectancy in this population can be measured in days.
Microvascular complications in type 2 diabetes
A newly diagnosed patient aged 65 years who embarks on intensified glycaemic control is substantially more likely to succumb to a cardiovascular event than to develop serious microvascular complications, but the demonstrated benefits of improved control upon microvascular outcomes must not be ignored. Both the UKPDS  and the Diabetes Control and Complications Trial (DCCT)  showed that a 1% reduction in HbA1c reduced the risk of these complications by about 25%. These considerations are more relevant for the younger patient with type 2 diabetes, but even by the age of 53 years (the mean age of enrolment for the UKPDS) the combined 10 year incidence of myocardial infarction (17.4%) and stroke (5%) was more than five times greater than the combined risk of renal failure (0.8%) and blindness (3.5%) . A calculation of NNT to prevent these serious microvascular events, quantified using a meta-analysis of data from the same four major studies [2, 17, 18, 19, 42], shows that it would be necessary to treat 272 patients with intensified glycaemic control for 5 years to prevent one person developing blindness in one eye, and 627 patients for 5 years to prevent one developing renal failure, although the effect is not statistically significant for either endpoint (Fig. 2; ESM Table 1). Both the lifetime risk of these microvascular outcomes and the added benefit of improved glucose control diminish with age. As an example, a 65-year-old with new-onset diabetes who has an HbA1c of 8.0% has an estimated 2/1,000 lifetime risk of blindness, falling to less than 1/1,000 by reducing HbA1c to 7.0% (NNT 500–1,000) . The authors of this analysis argue that efforts should be focused on those with HbA1c levels greater than 8%, since many more microvascular events will be prevented by this approach. The implication of these observations is that benefits accruing over decades should be taken into account in planning treatment for younger people, but that intensive glycaemic targets should be advised with some caution in older individuals .
Intensified glucose control: the costs
A comparison of the cost-effectiveness of intensified control of glucose, blood pressure and cholesterol in type 2 diabetes points strongly to the same conclusion . For example, the cost-effectiveness of lowering HbA1c from about 8% to 7% for a 65-year-old new-onset patient (based on UKPDS data and expressed in 1,997 US$) is $154,376 per QALY, as against $43,331 for cholesterol lowering and –$413 for blood pressure lowering. The costs of glucose control rise to $401,883 per QALY for those aged 75-84 years, and to $2.1 million over that age; in contrast, blood pressure control is cost-saving at every age below 85 years .
Intensified glucose control: the risks
Hyperglycaemia differs from cholesterol and blood pressure in another important respect, namely the complexity of glucose-lowering therapy. Management of risk factors implies medication for comparatively healthy individuals. The HMG-CoA reductase inhibitors, and to some degree the newer antihypertensive agents, provide simple regimens with drugs that are relatively free from side effects. Glucose-lowering therapies are, in contrast, associated with a wide range of unwanted consequences, for example weight gain, heart failure and osteopenic fractures for the thiazolidinediones, and weight gain and hypoglycaemia for the sulfonylureas. This side of the equation is rarely taken into consideration when intensified control is advocated. Furthermore, and in stark contrast to lipid-lowering or antihypertensive therapies, intensive glucose-lowering may require several injections each day , requires regular fingerprick blood testing and is associated with side effects that include hypoglycaemia and loss of consciousness, and perhaps an increased future risk of dementia . Our data (Fig. 2) suggest that 1,000 patients treated for 5 years would experience 47 additional hypoglycaemic events requiring assistance from another person in order to prevent about eight major (non-fatal) cardiovascular events over the same period. A study of 701 patients with type 2 diabetes assessed for quality of life ‘utilities’, where 1 corresponds to perfect health and 0 to death, rated the utility for intensified glycaemic treatment as 0.67, or the loss of one-third of full quality of life . In other words, this analysis suggests that it would be necessary to treat 119, 272 and 627 diabetic patients for 5 years for each person who benefits in terms of cardiovascular, eye or renal complications, respectively, using a treatment perceived to diminish quality of life by one-third.
Hyperglycaemia is a substantially weaker risk factor for CVD than cholesterol or blood pressure, and glucose-lowering interventions are correspondingly less effective. This awareness has yet to be reflected in standard guidelines . Furthermore, little attention has been paid to the unwanted effects of intensified therapy, and its low utility in those with established complications or a limited life expectancy. Treatment strategies that make sense at a population level may offer little advantage to the majority of those whose lives are affected by them, and can bring considerable inconvenience. Good glucose control does indeed offer protection against microvascular complications, cataracts and neuropathy, but the added benefits of an HbA1c of 7%, as against 8%, diminish with age and life expectancy. In such instances efforts and resources would be better directed to those with higher levels of HbA1c, who have much more to gain from attention to their glucose control. Each individual should indeed be encouraged to achieve the best possible compromise between glucose control and vascular risk, but fully informed consent should be the prelude to intensified therapy. This is not achieved when benefits are grossly overestimated, or when trials are presented in terms of relative risk reductions—‘25% fewer heart attacks’. Absolute risk reduction, the corresponding NNT, and the potential gain in life expectancy, are much more relevant in such discussions [48, 49], particularly when the recommended treatment impinges upon every aspect of a person’s life.
We would like to express thanks to R. Collins, R. Holman, I. Chalmers, P. Yudkin, C. Stehouwer and H. Price for valuable comments, advice and suggestions, and for provision of data during the process of writing this paper.
Duality of interest
The authors declare that there is no duality of interest associate with this manuscript.
- 1.International Diabetes Federation (2009) Diabetes Atlas, 4th edn. International Diabetes Federation, BrusselsGoogle Scholar
- 4.Bliss M (1983) The discovery of insulin. Paul Harris, EdinburghGoogle Scholar
- 6.4S Study Group (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389Google Scholar
- 11.WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet (1980) 316: 379-385.Google Scholar
- 16.University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Sections I and II. Diabetes 19(Suppl 2):747–830Google Scholar
- 21.Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403Google Scholar
- 30.Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351–357CrossRefPubMedGoogle Scholar
- 32.Nathan DM, Cleary PA, Backlund JY et al and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653CrossRefPubMedGoogle Scholar
- 33.Clarke PM, Gray AM, Briggs A et al and the UK Prospective Diabetes Study (UKDPS) Group (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47:1747–1759CrossRefPubMedGoogle Scholar
- 41.Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRefGoogle Scholar
- 47.Yudkin JS, Richter B, Gale EAM (2010) Intensified glucose control in type 2 diabetes—whose agenda? Lancet (in press)Google Scholar
- 48.Woloshin S, Schwartz LM, Welch HG (2008) Know your chances. Understanding health statistics. University of California Press, BerkeleyGoogle Scholar